Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Jan;77(1):30-39.
doi: 10.1136/annrheumdis-2017-211868. Epub 2017 Aug 30.

The EuroMyositis registry: an international collaborative tool to facilitate myositis research

Collaborators, Affiliations
Multicenter Study

The EuroMyositis registry: an international collaborative tool to facilitate myositis research

James B Lilleker et al. Ann Rheum Dis. 2018 Jan.

Abstract

Aims: The EuroMyositis Registry facilitates collaboration across the idiopathic inflammatory myopathy (IIM) research community. This inaugural report examines pooled Registry data.

Methods: Cross-sectional analysis of IIM cases from 11 countries was performed. Associations between clinical subtypes, extramuscular involvement, environmental exposures and medications were investigated.

Results: Of 3067 IIM cases, 69% were female. The most common IIM subtype was dermatomyositis (DM) (31%). Smoking was more frequent in connective tissue disease overlap cases (45%, OR 1.44, 95% CI 1.09 to 1.90, p=0.012). Smoking was associated with interstitial lung disease (ILD) (OR 1.32, 95% CI 1.06 to 1.65, p=0.013), dysphagia (OR 1.43, 95% CI 1.16 to 1.77, p=0.001), malignancy ever (OR 1.78, 95% CI 1.36 to 2.33, p<0.001) and cardiac involvement (OR 2.40, 95% CI 1.60 to 3.60, p<0.001).Dysphagia occurred in 39% and cardiac involvement in 9%; either occurrence was associated with higher Health Assessment Questionnaire (HAQ) scores (adjusted OR 1.79, 95% CI 1.43 to 2.23, p<0.001). HAQ scores were also higher in inclusion body myositis cases (adjusted OR 3.85, 95% CI 2.52 to 5.90, p<0.001). Malignancy (ever) occurred in 13%, most commonly in DM (20%, OR 2.06, 95% CI 1.65 to 2.57, p<0.001).ILD occurred in 30%, most frequently in antisynthetase syndrome (71%, OR 10.7, 95% CI 8.6 to 13.4, p<0.001). Rash characteristics differed between adult-onset and juvenile-onset DM cases ('V' sign: 56% DM vs 16% juvenile-DM, OR 0.16, 95% CI 0.07 to 0.36, p<0.001). Glucocorticoids were used in 98% of cases, methotrexate in 71% and azathioprine in 51%.

Conclusion: This large multicentre cohort demonstrates the importance of extramuscular involvement in patients with IIM, its association with smoking and its influence on disease severity. Our findings emphasise that IIM is a multisystem inflammatory disease and will help inform prognosis and clinical management of patients.

Keywords: Disease registries; Myositis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Onset of malignancy in relation to date of diagnosis of idiopathic inflammatory myopathy (IIM) for cases with cancer-associated myositis. Month 0 indicates date of IIM diagnosis.

Comment in

References

    1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;372:1734–47. 10.1056/NEJMra1402225 - DOI - PubMed
    1. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280:8–23. 10.1111/joim.12451 - DOI - PubMed
    1. Furst DE, Amato AA, Iorga ŞR, et al. . Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012;45:676–83. 10.1002/mus.23302 - DOI - PubMed
    1. Lilleker J, Murphy S, Cooper R. Selected aspects of the current management of myositis. Ther Adv Musculoskelet Dis 2016;8:136–44. 10.1177/1759720X16655126 - DOI - PMC - PubMed
    1. Gordon PA, Winer JB, Hoogendijk JE, et al. . Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;8:CD003643 10.1002/14651858.CD003643.pub4 - DOI - PMC - PubMed

Publication types